Obiettivo "T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to allow the full potential of CAR therapy to be unleashed.At present, CAR therapy requires a bespoke autologous therapeutic product for each patient. This greatly limits practicality, scalability and commercialisation. The development of a strategy for creation of universal engineered T-cells is the first key aim of this consortium. There is an increased appreciation of the immunological hostilities (CAR) T-cells face in the tumour microenvironment, and prevention of this local immune suppressive effect will likely be critical in permitting effective tumour control. The second main aim of this proposal is therefore to engineer CAR T-cells to be resistant to the hostile microenvironment. CAR T-cells can only be effective if they can access the tumour site. Exploiting the fact that neo-angiogenesis is a hallmark of neoplastic progression, the third aim of the consortium is to utilise endothelial cues of neo-angiogenesis to direct CAR T-cell migration and activity.The central technological theme of this consortium is the application of TALEN-mediated gene editing strategies alongside genetic modification with integrating vectors. Using this approach, we will implement a clinical study of “universal” CAR T-cells in refractory lymphoma. Further, this work will be complemented with highly focused development of T-cells which are resistant to hostile microenvironments and which can home to sites of neovascularization. The legacy this consortium wishes is commercialization of universal CAR therapy for a broad swathe of human cancers." Campo scientifico medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesclinical medicineoncology Programma(i) FP7-HEALTH - Specific Programme "Cooperation": Health Argomento(i) HEALTH.2013.2.4.1-2 - Strengthening the cancer patient's immune system Invito a presentare proposte FP7-HEALTH-2013-INNOVATION-1 Vedi altri progetti per questo bando Meccanismo di finanziamento CP-FP - Small or medium-scale focused research project Coordinatore UNIVERSITY COLLEGE LONDON Contributo UE € 2 646 887,00 Indirizzo GOWER STREET WC1E 6BT LONDON Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Martin Scott (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Partecipanti (5) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto CELLECTICS THERAPEUTICS SAS Partecipazione conclusa Francia Contributo UE Nessun dato Indirizzo RUE DE LA CROIX DE JARRY 8 75013 PARIS Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Julianne Smith (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Costo totale Nessun dato CELLECTIS SA Francia Contributo UE € 1 448 140,00 Indirizzo RUE JEAN ANTOINE DE BAIF 12 75013 PARIS Mostra sulla mappa Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Julianne Smith (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato PHILOGEN SPA Italia Contributo UE € 625 900,00 Indirizzo PIAZZA LA LIZZA 7 53100 Siena Mostra sulla mappa Regione Centro (IT) Toscana Siena Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Laura Baldi (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS Paesi Bassi Contributo UE € 640 980,00 Indirizzo PLESMANLAAN 121 1066 CX Amsterdam Mostra sulla mappa Regione West-Nederland Noord-Holland Groot-Amsterdam Tipo di attività Research Organisations Contatto amministrativo Henri Van Luenen (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato University of Zurich Svizzera Contributo UE € 569 244,00 Indirizzo RAMISTRASSE 71 8006 ZURICH Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Burkhard Becher (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato